GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BUE:BIIB) » Definitions » EV-to-EBITDA

Biogen (BUE:BIIB) EV-to-EBITDA : 12.20 (As of Dec. 15, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Biogen EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Biogen's enterprise value is ARS27,303,313 Mil. Biogen's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was ARS2,237,961 Mil. Therefore, Biogen's EV-to-EBITDA for today is 12.20.

The historical rank and industry rank for Biogen's EV-to-EBITDA or its related term are showing as below:

BUE:BIIB' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.43   Med: 10.46   Max: 21.96
Current: 9.59

During the past 13 years, the highest EV-to-EBITDA of Biogen was 21.96. The lowest was 5.43. And the median was 10.46.

BUE:BIIB's EV-to-EBITDA is ranked better than
67.41% of 718 companies
in the Drug Manufacturers industry
Industry Median: 14.21 vs BUE:BIIB: 9.59

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-12-15), Biogen's stock price is ARS12700.00. Biogen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was ARS9002.390. Therefore, Biogen's PE Ratio (TTM) for today is 1.41.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Biogen EV-to-EBITDA Historical Data

The historical data trend for Biogen's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen EV-to-EBITDA Chart

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.87 7.41 13.59 9.55 21.48

Biogen Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.01 21.48 17.61 17.80 11.87

Competitive Comparison of Biogen's EV-to-EBITDA

For the Drug Manufacturers - General subindustry, Biogen's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Biogen's EV-to-EBITDA falls into.



Biogen EV-to-EBITDA Calculation

Biogen's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=27303313.475/2237960.669
=12.20

Biogen's current Enterprise Value is ARS27,303,313 Mil.
Biogen's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS2,237,961 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biogen  (BUE:BIIB) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Biogen's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=12700.00/9002.390
=1.41

Biogen's share price for today is ARS12700.00.
Biogen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS9002.390.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Biogen EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Biogen's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen Business Description

Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.